Journal article
Pre-Stroke CHADS2 and CHA2DS2-VASc Scores Are Useful in Stratifying Three-Month Outcomes in Patients with and without Atrial Fibrillation collab on behalf of the VISTA collaborators
HTH Tu, BCV Campbell, A Meretoja, L Churilov, KR Lees, GA Donnan, SM Davis
Cerebrovascular Diseases | KARGER | Published : 2013
DOI: 10.1159/000353670
Abstract
Background: CHADS2 and CHA2DS2-VASc scores are validated tools for assessing stroke risk in patients with atrial fibrillation (AF). We investigated whether these scores are associated with 3-month stroke outcomes and evaluated the utility of these scores in stratifying 3-month stroke outcomes in both patients with and without AF. Methods: We analysed 6,612 acute ischaemic stroke patients from the Virtual International Stroke Trials Archive who received either placebo or ineffective active treatments not associated with significant cardiac complications. Outcomes included 3-month mortality, good functional outcomes defined as modified Rankin Scale score ≤1 and serious cardiac adverse events (..
View full abstractGrants
Funding Acknowledgements
Dr. Tu has received research funding from the Royal Melbourne Hospital Neuroscience Foundation. Dr. Campbell has received honoraria for speaking in educational symposia from Novartis and Boehringer Ingelheim and compensation for consultancy from H. Lundbeck A/S. Dr. Meretoja has received honoraria for speaking in educational symposia and compensation for consultancy with Boehringer Ingelheim, travel expenses from H. Lundbeck A/S and research funding from Sigrid Juselius and Biomedicum Helsinki Foundations. Dr. Churilov has received research funding from the Australian National Health and Medical Research Council, the Australian Commonwealth Scientific and Research Organization and is an editorial board member for Journal of Decision Systems, Operations Research for Health Care, Health Systems, Health Care Management Science, and International Journal of Stroke. Prof. Lees has received honoraria from Astellas, Asubio, Bayer, Boehringer Ingelheim, Johnson & Johnson, Lundbeck, Mitsubishi, Photothera, Sanofi- Aventis, Servier, Talecris, Wyeth, has held grant funding from the Chief Scientist Office of Scotland for a trial of AF, and serves as an editor for Stroke. Prof. Donnan has received research funding from the Australian National Health and Medical Research Council, the Australian Commonwealth Scientific and Research Organization and serves as an editorial board member for Stroke, Cerebrovascular Diseases, Journal of Clinical Neuroscience, and International Journal of Stroke